– FRANCE, Marseille – Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, announced the appointment of Dr. Jean-Christophe Dantonel (Ph.D.) to its Board of Directors, brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
About Jean-Christophe Dantonel
Jean-Christophe Dantonel has extensive experience in academia, research, governance, and business and is recognized for his exceptional contributions to advancing biotech projects and driving groundbreaking research initiatives.
“Vect-Horus has demonstrated longevity and solidity that are rare among young biotech companies. This undeniably demonstrates the quality of science and the know-how of the teams. Positioned in a market with enormous potential, Vect-Horus has demonstrated its ability to forge demanding partnerships. It is with great pleasure that I join the Vect-Horus Board of Directors to contribute to this ambition,” said Jean-Christophe Dantonel.
Jean-Christophe Dantonel is a Board Member at ophthalmological digital health company Tilak Healthcare and Managing Partner of medical venture capital firm iBionext and was previously a Board Member at EUROAPI. He was previously a Counselor at France’s Ministry of Higher Education and Research and spent six years with the French biomedical research institute INSERM as Project Manager, where responsibilities included setting up and following up clinical trials.
Jean-Christophe Dantonel holds a PhD in Genetics, Molecular and Cellular Biology from the University of Strasbourg and an MBA from Sciences Po.
About Vect-Horus
Vect-Horus designs and develops vectors that facilitate the targeting and delivery of therapeutic or imaging agents to organs, including the brain, and to tumors. Founded in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS, and Aix Marseille University), formerly headed by Dr Michel Khrestchatisky, co-founder of the company. Vect-Horus has 42 employees (most in R&D).
For more information: https://www.vect-horus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.